Improving Lives

Neurotech International

Investor Presentation

Dr Tom Duthy
Executive Director

10 July 2024

Disclaimer

IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as ‘intends’, ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’ or ‘expects’. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech’s control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

A short video on Neurotech

Corporate / Capital Summary

$0.074
Share price
(as at 8 Jul 2024)

$75.2M
Market capitalisation

$13.6M
Pro-Forma Cash 31 March ’24*

~2,450
No. of shareholders

1016.7M
Share on issue

176.5M
Options^

$6.5M
FY23 R&D Exp.
(up from $2.6M in FY22)

45.4%
Top 20 Holders

- 31 March cash balance of $4.2 million + Equity Placement (net of fees of $9.4m)
- ^Inc Listed, Unlisted Investor Options, Executive, Director options at various strike prices between $0.06 to $0.16 as at 3 June 2024

Neurotech Four Core Strategies

Neurotech International



Focus on Paediatric Patients



Focus On Rare Neurological Disorders with Neuroinflammation

Focus on Partnering with Key Opinion Leaders / Clinicians



Focus On Drug Product Development

Therapeutic Agent: NTI164

High potency, Broad Spectrum Cannabinoid Formulation in Oil, *C. sativa L.* (Plant Derived)

- THC < 0.3%
- Major constituent Cannabidiolic acid (CBDA)
- Minor constituents include other cannabinoids: CBD, CBG, other + terpenes

Convenient 1x or 2x (split dose) oral formulation in oil, ideal format for pediatric patients 20mg/kg (CBDA)

NTI164 is <u>not</u> a low dose CBD oil to be sold over-the-counter

- Entourage Effect
- Neuroprotective
- Anti- Neuroinflammatory

Intellectual Property – 2024

Strong Patent Position

Neurotech has three patent families to underpin future worldwide commercialisation in neurological applications of NTI164. Two families have now entered the national phase and one family has entered the international (PCT) phase.

Composition

Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) and a unique combination of 'rarer' cannabinoids: CBDA, CBC, CBDP, CBDB & CBN

Lodged Oct 2021

Combination

The application, formulation and use of NTI164

Lodged Oct 2021

Methods

The application, formulation and use of NTI164 in paediatric patients

Lodged Oct 2022

Other IP & Barriers to Entry

Vertically Integrated: Seed to Patient Controlled

(Trade Secret: continuity of production to SOP, extraction(s))



Orphan Drug Designation(s)

10 Years	Market Exclusivity from Approval – Europe
7 Years	Market Exclusivity from Approval – United States

PANDAS/PANS

Rett Syndrome

Pending

Clinical Pipeline – 2024

Neurotech International



1. Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
2. Autism Spectrum Disorder

Our Target Markets

Lack of effective therapies, significant unmet medical need

Annual Drug Therapy Market opportunity

Autism Spectrum Disorder (ASD)	Rett Syndrome	PANDAS/PANS	Cerebral Palsy (CP)
US$2 billion*	US$2 billion	US$1.4 billion[1]	US$4.3 billion
• Prevalence of ~2.0M <18 yr. patients in the US • 2 Approved Drugs (* limited use) • Risperidone, Aripiprazole	• Prevalence of ~15,000 patients in the US • 1 Approved Drug • Trofinetide (DAYBUE™)	• Incidence of ~6,000 patients <18 yr. in the US[1] • No FDA/EMA Approved Drug	• Incidence of ~500,000 <18 yr. patients in the US • 2 Approved Drugs for spastic CP • Baclofen, Botox

ndis

Orphan

Orphan

$6.1 Billion

Implied annual cost of ASD to NDIS based on average ASD funding of $32,800 per annum e.g. physio, psychology, speech therapy, support workers

1. Neurotech Estimate based on: Wald ER, et al. Estimate of the incidence of PANDAS and PANS in 3 primary care populations. Front Pediatr. 2023 Sep 21; EU/UK: 8,000 pts / US: 6,000 pts <18 years based on annual intravenous immunoglobulin (IVIG) cost of ~US$100k (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019941/)

CBD OTC Market - Australia

Highly Competitive, Low Margin, Low Price, Lack of Differentiation, Stringent Regulatory Oversight – Not the Market for NTI164

48
CBD Products Registered on the ARTG[1]

44/35
Domestic Manufacturers / Importers of Cannabis Products on ODC[2] Website

0
Number of over-the-counter (OTC) CBD products able to make a substantiated medical claim[3]

~$0.05
Average Cost per mg CBD
(↓↓ 76% since 2018)

150mg
Max. amount of pure CBD per day allowed under Schedule 3 (pharmacist-only medicine)
(sub-therapeutic)

165 / $2.3M
The number of infringements and total fines issued by TGA in last two years (unlawful advertising)[4]

1. Australian Register of Therapeutic Goods (ARTG)
2. Office of Drug Control (ODC)
3. Approved by the Therapeutic Goods Administration (TGA) for one or more medical conditions via well-designed, valid clinical trials
4. Source: TGA

Why a Prescription Medicine Pathway for NTI164?

Neurotech International

Epidiolex® : The only FDA, TGA, EMA approved high potency CBD-only oil (Schedule 4)

What does it do?

- Approved to manage seizures in 3 orphan ‘rare’ neuro disorders
- In….Dravet Syndrome, Lennox-Gaustat Syndrome and Tuberous Sclerosis Complex
- Representing….. 29,000 children in the USA
- Developer (GW Pharma) acquired for **US$7.2Bn** in 2021 by Jazz Pharma

How are sales?

- 2022 Sales **US$731M**
- 2024 sales expectations **US$1Bn**[4]
- Sales Compound Annual Growth Rate (CAGR) 2018-2022 **253%**

Where are the CBD cannibals?

- ….Absent, as little to no evidence of off-label substitution with other CBDs
- Reimbursement available at a sig. high selling price (A$24k in AU, US$33k in USA)
- Regulatory approved, evidence of benefit, doctor conservatism

1. Based on 73m children with 1/15,700 living with disease
2. https://www.lgsfoundation.org/
3. Tuberous Sclerosis Complex (TSC)
4. Jazz Pharmaceuticals

NTI164 – Ideal Target Product Profile

- **Prescription Only Medicine**
- **FDA, EMA, TGA Approved**
- **Multiple Paediatric Neurological Disorders**
- **Premium Pricing Reflecting Clinical Investment**
- **Reimbursed**
- **Orphan Designations + Other Regulatory Levers**

1. Based on 73m children with 1/15,700 living with disease
2. https://www.lgsfoundation.org/
3. Tuberous Sclerosis Complex (TSC)
4. Jazz Pharmaceuticals

Epidiolex® – Actual Target Product Profile

Neurotech International

- **Prescription Only Medicine**
- **FDA, EMA, TGA Approved**
- **Multiple Paediatric Neurological Disorders**
- **Premium Pricing Reflecting Clinical Investment**
- **Reimbursed**
- **Orphan Designations + Other Regulatory Levers**

NTI164……not re-inventing the wheel, simply aligning to a proven model

1. Based on 73m children with 1/15,700 living with disease
2. https://www.lgsfoundation.org/
3. Tuberous Sclerosis Complex (TSC)
4. Jazz Pharmaceuticals

Autism | Rett | PANDAS/PANS

*"The goals of treatment for **Autism** are to improve core deficits in social communication and social interactions and minimize the impact of restricted behaviours, with an overarching goal to help children develop greater functional skills and independence."* [1]

*"Caregivers of children with **Rett** experience the illness as being like an "obstacle course", where they must continuously overcome hurdles. These include hindrances for finding responses to their symptoms and achieving a diagnosis, for managing the treatment and daily care, and for finding the essential financial resources to meet all the expenses generated by the illness."* [2]

*"We encourage clinicians, teachers, providers, extended family, and friends to understand the human aspects of **PANDAS/PANS** as symptoms are often so distressing, causing high levels of caregiver burden."* [3]

1. Weitlauf AS, McPheeters ML, Peters B, et al. Therapies for Children With Autism Spectrum Disorder: Behavioural Interventions Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Aug. (Comparative Effectiveness Review, No. 137.) Introduction.
2. Palacios-Ceña D, Famoso-Pérez P, Salom-Moreno J, Carrasco-Garrido P, Pérez-Corrales J, Paras-Bravo P, Güeita-Rodriguez J. "Living an Obstacle Course": A Qualitative Study Examining the Experiences of Caregivers of Children with Rett Syndrome. International Journal of Environmental Research and Public Health. 2019; 16(1):41
3. https://aspire.care/what-is-pans/caregiver-experience/

No Safety concerns – across all trials to date

94 children across all trials (inc. extensions reported to date, max 2 years)

Autism | Rett | PANDAS/PANS

Normal

Kidney/Liver Function

Vital Signs

Blood Chemistry

Minor Adverse Events

Mild Nausea/vomiting ~5-15%

No diarrhoea

No weight loss

One single Serious Adverse Event (SAE) recorded across all trials – hives (Rett). Incidence of ~1% (1/94)

NT1164 Efficacy is Strong and Durable

Neurotech International

Autism

56% Improvement in Severity of illness at 12 weeks



46% Patients Much Improved / Improved at 8 weeks

Significant Improvements in Adaptive Behaviours

Rett

30% Improvement in RSBQ, 205% from 4-12 weeks



60% Improvement in patient/caregiver quality of life

93% of patients improved on 4 core Rett symptoms

PANDAS/PANS

38% Improvement in Disease Severity at 52 weeks



45% Improvement in anxiety / depression at 52 weeks

Recent Clinician Developments

A/Prof Carolyn Ellaway Appointed Chief Medical Officer (CMO)

- Internationally recognised clinical geneticist and was the lead Investigator on the Company's successful Phase I/II Rett Syndrome clinical trial
- Key opinion leader engagement along with overseeing the development and execution of regulatory and clinical trial strategies
- *"…..I was the Principal Investigator on the trial and observed significant improvements in my patients after just 12 weeks of treatment"*

International PANDAS/PANS Expert Panel Established

- International panel of leading PANDAS/PANS clinicians to build expert global consensus and drive awareness, led by Professor Russell Dale (Principal Investigator on Neurotech Phase I/II trial
- Professor Jennifer Frankovich, Department of Pediatrics - Division of Allergy, Immunology & Rheumatology, Stanford Medicine
- Adj Assoc Prof Terrence Thomas, Head Neurology Service & Senior Consultant Head at KK's Women's and Children's Hospital and Singapore General Hospital, Singapore

Key Milestones – NTI164

1H CY2024

- HREC/TGA Approval Cerebral Palsy Phase I/II Clinical Trial
- 24-week PANDAS/PANS Phase I/II Clinical Trial Data
- Rett Syndrome Phase I/II 52-week Extension HREC Approval
- Results of ASD Phase II/III Clinical Trial
- Top-line Rett Syndrome Phase I/II Clinical Trial data
- Results of Rett Syndrome Phase I/II Clinical Trial – full data
- Meeting outcome – TGA[1] Regulatory Advice
- Metabologenomic data from Phase I/II PANDAS/PANS Clinical Trial
  - Pending final analysis by Prof. Dale team (Q3)

2H CY2024

- Appointment of A/Prof Carolyn Ellaway as CMO
- Filing of Orphan Drug Designation USA – PANDAS/PANS
- Additional Phase II/III 12 Week Cross-Over Results - ASD
- Orphan Drug Designation USA – Rett Syndrome
- Orphan Drug Designation USA – PANDAS/PANS
- Orphan Drug Designation Europe – Rett Syndrome
- Orphan Drug Designation Europe – PANDAS/PANS
- Presentation of Phase I/II Rett Syndrome data at international Rett meeting
- FDA IND / EMA[2] toxicology
- Commence Phase I/II Cerebral Palsy Clinical Trial
- Publications for ASD Phase I/II + pre-clinical NTI164 results (was 1H)

1. Therapeutic Goods Administration (TGA)
2. Food and Drug Administration (FDA), European Medicines Agency (EMA)

Outlook

- **Completed $10.0 million capital raise in April, $13.6 million in available pro-forma funds: well-funded to accelerate development activities in Australia and US, EU**
- **Continued safety/efficacy data releases across 3 indications (ASD, PANDAS/PANS, Rett) as patients enter or are maintained in open-label extensions**
- **Clinical, regulatory, commercial strategies in development – anticipate finalisation early Q3 CY2024**
- **Strong focus on expedited path(s) to market given NTI164 efficacy and safety in very serious neurological disorders in children lacking effective therapies**

Neurotech International

Contact Details

Dr Tom Duthy
Executive Director
td@neurotechinternational.com
+61 402 493 727

*This presentation has been authorised by the Board of Neurotech International Limited

www.neurotechinternational.com